Oncopeptides AB

Oncopeptides AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from PDC platform, PEPAXTO®(melphalan flufenamide), has been launched in the U.S., for the treatment of adult patients with relapsed or refractory multiple myeloma. Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE. Oncopeptides is developing several new compounds based on the PDC platform. The first one is expected to enter into clinical development in 2021.Oncopeptides has approximately 300 coworkers. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Oncopeptides appoints Klaas Bakker as new Chief Medical Officer

Tue, Aug 20, 2019 08:00 CET

Stockholm - August 20, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announces that Klaas Bakker has been appointed as the new Chief Medical Officer (CMO) for Oncopeptides, starting in November.Johan Harmenberg has reached retirement age and as the company continues to expand its activities, Johan has decided to step down as CMO but continue to work as a member of the company's medical team. From 2015 to present Klaas has worked at AstraZeneca in different roles with increasing responsibility and seniority, most recently as VP Medical for their Tagrisso -TDR Franchise with global

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Oncopeptides appoints Klaas Bakker as new Chief Medical Officer

Subscribe

Media